The United States remains the global leader in biotechnology, but its advantage over China is shrinking and could disappear by 2030, according to the latest Biotech Scorecard from the Special Competitive Studies Project (SCSP), a nonprofit and nonpartisan initiative that advises on strengthening America's long-term competitiveness in artificial intelligence. The report's warning carries weight because biotechnology is not a single industry but a web of supply chains, manufacturing capacity, data holdings, and regulatory speed—areas where leadership can shift quickly and where the consequences for national competitiveness and security are significant.
SCSP's Tech Scorecard methodology assesses five elements: Innovation Leadership, Market Ecosystem, Talent Pipeline, Industrial Capacity, and National Leverage. The United States leads in the first three, but China appears ahead in Industrial Capacity and National Leverage. That split matters because it suggests American strength is concentrated in early-stage research and finance, while China is building the physical and policy infrastructure to convert scientific promise into marketed products. According to the report, China's position is strengthened by two decades of deliberate national strategy that is now producing results. By contrast, the American position is described as “a return on research investments made decades ago, sustained by a capital market that rewards its strongest performers.”
The scorecard focuses on biopharmaceuticals to illustrate China's acceleration. Most U.S. government funding for biotechnology goes to basic research, and the report notes a lack of urgency in expanding government support for commercializing drug products. Approval timelines for drugs entering clinical trials and going to domestic markets are driven by government policy and can accelerate or slow the pipeline of innovation, the SCSP authors emphasize. China, meanwhile, is more active in supporting biotech startups through the process of acquiring capital to build pilot capacity, scale up production, and reach markets without waiting for a definitive return on those expanded investments. Its tools include preferential taxation, below-market lending, and direct subsidies—levers the U.S. largely leaves to the private sector.
The implications extend beyond today's balance sheet. As artificial intelligence allows scientists to predict molecular activity, the expensive early stages of drug discovery will likely decrease, and competitive advantage will shift to testing, manufacturing, and commercializing a promising drug candidate. “Whether the United States retains its edge depends both on model quality and how quickly it can move a computationally generated candidate through trials, approval, and manufacture before a competitor improves on it,” the report states. In practical terms, the scorecard signals that American policymakers cannot assume a durable lead based on past research dominance. The full report is available at scsp.ai, and the findings were distributed through (NewsUSA).
